Wednesday, October 14, 2026
ExploreSearch
Finance Via News

Banking M&A

3 articles

Columbia Financial Raises $1.67B in IPO, Closes Northfield Bancorp Buy One Day Later

Columbia Financial Raises $1.67B in IPO, Closes Northfield Bancorp Buy One Day Later

Columbia Financial priced its second-step conversion at $10.00 per share, selling over 167 million shares to raise roughly $1.67 billion ahead of a July 21, 2026 Nasdaq debut. The company closes its acquisition of Northfield Bancorp on July 20, 2026, offering shareholders $14.25 cash or 1.425 shares per Northfield share.

LM Salvado•
ABN AMRO Acquires NIBC as European Banks Pursue Scale in Consolidation Wave

ABN AMRO Acquires NIBC as European Banks Pursue Scale in Consolidation Wave

ABN AMRO's acquisition of NIBC and RBC's $13.5B purchase of HSBC Canada mark a European banking consolidation wave as institutions seek scale advantages. Leadership transitions at ING and ABN AMRO accompany structural changes, while Bank of Åland distributes EUR 2.75 per share dividends amid sector repositioning.

ViaNews Editorial Team (Finance)•
PNC completes six acquisitions in four years as regional banks race to offset margin pressure

PNC completes six acquisitions in four years as regional banks race to offset margin pressure

PNC Financial closed deals for BBVA USA, Linga, Signature Bank assets, and gained approval for FirstBank and Aqueduct Capital Group between 2021-2025. The consolidation wave reflects industry-wide pressure on net interest margins, with PNC forecasting just 1.5% sequential NII growth in Q4 2025 despite its aggressive expansion.

ViaNews Editorial Team (Finance)•
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com